期刊文献+

血管生成素样蛋白2在乳腺癌组织与血清中的表达及临床意义 被引量:6

Clinical significance of Angptl2 expression in tumor tissue and serum in patients with breast cancer
下载PDF
导出
摘要 目的:分析血管生成素样蛋白2(angiopoietin-like protein 2,Angptl2)在乳腺癌组织和血清中的表达。方法乳腺癌和癌旁组织蜡块78例,免疫组化法检测患者术前与术后血清Angptl2蛋白的表达,酶联免疫吸附试验法(ELISA)检测患者血清 Angptl2水平,并分析 Angptl2蛋白的表达与临床病理特征及无进展生存( progression-free survival,PFS)的关系。受试者特征( the receiver operating characteristics,ROC)曲线分析血清 Angptl2诊断乳腺癌的敏感性与特异性。结果乳腺癌组织标本中,Angptl2表达阳性64例(82.1%),其中,Angptl2高/中表达在癌组织和癌旁组织分别为42例(53.8%)和6例(7.7%)(P ﹤0.01)。Angptl2高/中表达与患者淋巴结转移有关,并导致 PFS 缩短。乳腺癌患者血清中 Angptl2水平为(218.72±88.02)ng/ ml,对照组为(80.88±30.59)ng/ ml,两组比较差异有统计学意义(P ﹤0.01)。曲线下面积(area under the curve,AUC)为0.909,诊断效能良好。术后1周 Angptl2水平下降至(142.43±60.29)ng/ ml,但仍高于对照组,较差异有统计学意义(P ﹤0.01)。结论乳腺癌患者癌组织和血清中 Angptl2表达均升高,Angptl2可作为乳腺癌早期诊断与预后判断的标志物。 Objective To explore Angptl2(angiopoietin-like protein 2)expression in tumor tis-sue and serum in patients with breast cancer(BC). Methods A total of 78 BC patients were enrolled in this study. Immunohistochemistry was used to detect Angptl2 expression in tumor and adjacent normal tis-sues. Preoperative and postoperative serum Angptl2 levels were determined via ELISA. Correlation among Angptl2 expression,clinicopathological factors and progression-free survival(PFS)were further evalua-ted. The receiver operating characteristics(ROC)curve was constructed to describe diagnostic specificity and sensitivity. Results Angptl2 was positively expressed in 64(82. 1% )cases. The rates of high and moderate expression of Angpt l2 in tumor and adjacent tissues were 53. 8%(42 / 78)and 7. 7%(6 / 78), respectively(P﹤0. 001). Moreover,the elevated Angptl2 protein was significantly associated with lymph metastasis and adverse PFS. In addition,serum Angptl2 level in BC patients was significantly higher than that in benign controls[(218. 72 ± 88. 02)vs(80. 88 ± 30. 59)ng/ ml,P ﹤ 0. 01]. The area under the curve(AUC)was 0. 909,which indicated a good function for diagnosis. Postoperative serum Angptl2 level was decreased to(142. 43 ± 60. 29)ng/ ml,but still higher than that in controls(P ﹤ 0. 01). Conclusion The expression of Angptl2 may increase in tumor tissue and serum of BC and it may be a potential tumor marker for diagnosis and prognosis.
出处 《临床外科杂志》 2015年第11期824-826,共3页 Journal of Clinical Surgery
关键词 乳腺癌 血管生成素样蛋白 2 诊断 预后 breast cancer diagnosis prognosis
  • 相关文献

参考文献10

二级参考文献59

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2徐兵河.针对人表皮生长因子受体信号传导途径的乳腺癌分子靶向治疗新进展[J].癌症进展,2007,5(3):219-224. 被引量:3
  • 3Kim BK,Ahn SH,Seong JS. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma[J].{H}Liver International,2011,(03):369-376.
  • 4Kasprzyk M,Dyszkiewicz W,Piwkowski C. Prognostic value of DNA ploidy:5-year follow-up of patients with respectable squamous cell carcinoma(SCC)of the lung[J].{H}Lung Cancer,2006,(02):201-206.
  • 5Meister M,Schirmacher P,Dienemann H. Mutational status of the epidermal growth factor receptor(EGFR)gene in thymomas and thymic carcinomas[J].{H}CANCER LETTERS,2007,(02):186-191.
  • 6Johnston SR,Leary A. Lapatinib:a novel EGFR/HER2 tyrosine kinase inhibitor for cancer[J].{H}Drugs Today(Barc),2006,(07):441-453.
  • 7Gown AM. Current issues in ER and HER-2 testing by IHC in breast cancer[J].{H}Modern Pathology,2008,(Suppl 2):S8-S15.
  • 8Parkin DM, Bray F, Felay J, et al. Global cancer statistics, 2002 [ J ]. CA cancer J clin,2005,55 (2) :74-108.
  • 9Foulkes WD, Smith IE, Reis-Filho JS, et al. Triple-negative tumors [J]. N Engl J Med,2010,363(20) :1938-1948.
  • 10Carey LA,Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study E J 1. JAMA, 2006, 295 (21) :2492-2502.

共引文献20

同被引文献54

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部